GGrantIndex
← Leaderboards

Herbert Hurwitz

Duke University

$2,172,341
Attributed
$2,172,341
Total exposure
4
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$2,172,341 · 4

By mechanism

M01$2,172,341 · 4

Top collaborators

No co-investigators on record.

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectClinical ResearchClinical Trial Phase INeoplasm /Cancer ChemotherapyHuman Therapy EvaluationAntineoplasticsDrug Adverse EffectDrug Screening /EvaluationPharmacokineticsUracil AnalogFluorouracilCombination ChemotherapyCombination Cancer TherapyNeoplasm /Cancer Radiation TherapyPancreas NeoplasmsStomach NeoplasmsDosageOral AdministrationPiperidineNeoplasm /CancerDrug Administration Rate /DurationEnzyme InhibitorsBlood PressureNitric Oxide

Grant awards (18)

BIOMARKER AND CLINICAL EVALUATION OF BEVACIZUMAB (AVASTIN) TO DETERMINE THE ROLE$101,992
M01 · FY2005 · RR
Nitric Oxide in Anti-VEGF Therapy$15,223
M01 · FY2004 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$117,022
M01 · FY2002 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$117,022
M01 · FY2002 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$117,022
M01 · FY2002 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$293,069
M01 · FY2001 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$293,069
M01 · FY2001 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$293,069
M01 · FY2001 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$117,022
M01 · FY2001 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$117,022
M01 · FY2001 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$117,022
M01 · FY2001 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$117,022
M01 · FY2001 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$117,022
M01 · FY2001 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$117,022
M01 · FY2001 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$40,907
M01 · FY2000 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$40,907
M01 · FY2000 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$40,907
M01 · FY2000 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$0
M01 · FY2000 · RR